NCT01677884View on ClinicalTrials.gov

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Colorectal Neoplasms
Interventions
DRUG

Bevacizumab

Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1

DRUG

Capecitabine

Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4

DRUG

Irinotecan

Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)

Trial Locations (1)

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT01677884 - Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy | Biotech Hunter | Biotech Hunter